4-5 July 2011

Grand Copthorne Hotel, Singapore

Global Life Sciences M&A and Innovative Strategic Alliances -

Panel 1 - An overview of current and future trends

• How are life sciences companies using the lessons learnt from the implications of the economic downturn and the new perspective and understanding of the industry to prepare for the recovery and tap into newfound opportunities?
• As the broadening stream of non-traditional players in the healthcare arena is entering the life sciences ecosystem, how are life sciences companies building innovative strategic alliances and collaborations to leverage on other player’s assets and capabilities to create competitive advantage?
• What is the new normal for the life sciences industry?

Panel 2 - The changing financing paradigm in the life sciences industry

• Exploring current investment opportunities alternative methods of financing, capital raising and risk sharing: project-based financing, royalty-stream financing, reverse mergers, government grants and incentives, disease foundation grants, high net-worth individuals, corporate collaborations etc
• An outlook of the current life sciences IPO market
• An outlook of the current VC funding trend for life sciences

23 June 2011

Pharmazentrum

University of Basel

Switzerland

Succeeding With a Special Business Model

4th edition of Life Science Forum Basel

5-6 Apr 2011  Pharma Innovations & Drug Development India, Mumbai, India

Speaker : An International Look: Partnering with Indian Companies

• What are the new trends pushing the West to head to India for partnerships?

• Key guidelines a local company should have to attract Western partners

• Identifying areas India still needs to improve

Panelist : “An Overview of Successful Indian Collaborations”

1 Apr 2011

Swiss Biotech Industry :Challenges and Achievements

Biopolis,

Breakthrough Theatrette

 Keynote lecture

Biopharma Industry - Academia Partnerships

Oxaliplatin, a Blockbuster Case Study of Debiopharm SA

By Kim Bill, Vice President, Debiopharm Group, Founder ALSA

Panel: Opportunities in investing in early stage companies

• Assessing risks and returns in investing in early stage companies

• Developing stringent evaluation criteria and performing in-depth due diligence

• Investment and collaboration models that best suit Asian culture

Kim Bill, VP Corporate Development Debiopharm, Founder ALSA, Switzerland

Brian Baynes, Partner, Flagship Ventures, USA

Shengwan Lee, General Partner, Pac-Link Bioventures, Taiwan

Alex Suh, Founding Managing Director, California Technology Ventures, Jacobs Capital Group, USA

Moderator:

Alie Tigchelhoff, Managing Director, Utrecht Science Park, The Netherlands

Panel: Structuring high yield healthcare portfolio for maximum return

• identifying key performing sectors and emerging innovative companies
• performing critical due diligence in assessing key investment prospects: determining the best investment strategies, targeted returns and exit options
• assessing the performance of other healthcare funds in Asia

Mahendra G. Shah, Executive-In- Residence, Vivo Ventures, USA

Henry Nguyen, Managing General Partner, IDG Ventures, Vietnam

Davis Yang, Principal, BioVeda China Fund, China

Moderator:

Kim Bill, VP Corporate Development Debiopharm, Founder ALSA, Switzerland

30 Jan - 1 Feb, 2011 Swiss Pharma Licensing Group Annual Winter Conference, Flims, Switzerland

Searching for Excellence in Business Development & Licensing- People, Practice, Theory & Tools

Kim Bill - Conference Director

Archives 2010-2006